To our Patient Advocacy Partners,

As the coronavirus (COVID-19) continues to affect communities in the U.S. and around the world, our hearts go out to those impacted. We are operating with a high degree of care as we protect our employees and customers during this public health crisis. In this uncertain and rapidly-changing time, we are aware COVID-19 is having a real impact on our oncology patients, many of them at higher risk due to being immune compromised. I would like to personally thank all the healthcare professionals who are working in hospitals and centers around the country for the support you are providing at this critical time.

We believe it is our responsibility to prioritize two things:
• our commitment to supporting the health and safety of our employees, customers and patients and
• protecting our ability to manufacture and supply medicines, vaccines and consumer products for patients.

To that end, we want to ensure you are aware of the expanded access program (EAP) for belantamab mafodotin, an investigational immunoconjugate against B-cell maturation antigen (anti-BCMA) being evaluated in several studies as a treatment for multiple myeloma. The EAP is available to eligible multiple myeloma patients in the U.S. who have undergone stem cell transplant or are considered transplant ineligible and are refractory to previous treatment with a proteasome inhibitor, immunomodulatory drug, and anti-CD38 therapy.

For patients to be considered for enrollment in the EAP, they must be assessed according to specific inclusion and exclusion criteria by their treating physician. Additional information about the EAP protocol can be found on ClinicalTrials.gov (NCT03763370) or https://gsk-cu-portal.idea-point.com/.

For questions on the EAP, other GSK products and/or product availability, please contact the GSK Response Center at 1-888-825-5249. Healthcare professionals can also visit the GSK Medical Information website at www.gskusmedicalaffairs.com or call 877-475-6448.

More than ever, know we are committed to partnering to provide support to patients and our communities to ensure they continue to receive the care they need.

Sincerely,

Tania Small
Tania Small, MD
Vice President, Medical Oncology Franchise Head